No Coombs Test Needed in This Scenario
When both mother and baby are O positive, a direct antiglobulin test (DAT/Coombs test) is not required, as there is no ABO or Rh incompatibility to cause hemolytic disease. 1
Why Testing Is Not Indicated
The American Academy of Pediatrics guidelines are clear on this point: if the maternal blood is group O, Rh-positive, testing the cord blood for the infant's blood type and direct antibody test is optional but not required, provided there is appropriate surveillance, risk assessment before discharge, and follow-up 1.
In your case, both mother and baby are O+, meaning:
- No ABO incompatibility exists (both are type O)
- No Rh incompatibility exists (both are Rh positive)
- No risk of hemolytic disease from these major blood group systems
When DAT Testing IS Required
The AAP strongly recommends DAT testing only in specific scenarios 1:
- Mother is Rh-negative (regardless of baby's type)
- Mother has not had prenatal blood grouping
- Mother is type O and baby is type A or B (ABO incompatibility)
- Mother is type A or B and baby has incompatible type (less common)
What You Should Do Instead
Since testing isn't required, focus on clinical surveillance 1:
- Monitor for jaundice every 8-12 hours during hospital stay
- Assess bilirubin levels (transcutaneous or serum) if jaundice appears excessive for age
- Ensure adequate feeding (8-12 times daily for breastfed infants)
- Arrange appropriate follow-up within 1-2 days after discharge
Important Caveat
While O+/O+ pairing eliminates ABO and Rh incompatibility risk, rare causes of hemolytic disease still exist (anti-Kell, anti-Duffy, other minor antigens) 2. If the baby develops unexplained severe jaundice, rapid bilirubin rise (>0.2-0.3 mg/dL/hour), or anemia, then investigate further with DAT and other testing 3, 1. But routine screening is not indicated in your scenario.
The 2024 AAP phototherapy guidelines reinforce that DAT should be performed when investigating the cause of hyperbilirubinemia requiring treatment, not as universal screening in compatible blood types 3.